Page last updated: 2024-11-01

omeprazole and Polyarthritis

omeprazole has been researched along with Polyarthritis in 15 studies

Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.

Research Excerpts

ExcerptRelevanceReference
"To compare the safety and efficacy of celecoxib versus diclofenac slow release (SR) plus omeprazole in elderly arthritis patients."9.16Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial. ( Essex, MN; Kellner, HL; Li, C, 2012)
"In order to discover and develop drug-like anti-inflammatory agents against arthritis, based on "Hit" we found earlier and to overcome drawbacks of toxicity, twelve series of total 89 novel pyrimidine, pyrazolo[4,3-d]pyrimidine and thieno[3,2-d]pyrimidine derivatives were designed, synthesized and screened for their anti-inflammatory activity against NO and toxicity for normal liver cells (LO2)."8.02Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis. ( Chen, LZ; Huang, X; Liu, MM; Liu, XH; Ma, D; Shi, JB; Shu, HY; Wu, J; Yu, YL, 2021)
"To compare the safety and efficacy of celecoxib versus diclofenac slow release (SR) plus omeprazole in elderly arthritis patients."5.16Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial. ( Essex, MN; Kellner, HL; Li, C, 2012)
"A combination package containing delayed-release capsules of the proton pump inhibitor lansoprazole (15 mg once daily) and tablets of the NSAID naproxen (375 or 500 mg twice daily) has been approved for reducing the risk of NSAID-associated gastric ulcers in NSAID-requiring patients with a documented history of gastric ulcer."4.82Delayed-release lansoprazole plus naproxen. ( Curran, MP; Wellington, K, 2004)
"In order to discover and develop drug-like anti-inflammatory agents against arthritis, based on "Hit" we found earlier and to overcome drawbacks of toxicity, twelve series of total 89 novel pyrimidine, pyrazolo[4,3-d]pyrimidine and thieno[3,2-d]pyrimidine derivatives were designed, synthesized and screened for their anti-inflammatory activity against NO and toxicity for normal liver cells (LO2)."4.02Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis. ( Chen, LZ; Huang, X; Liu, MM; Liu, XH; Ma, D; Shi, JB; Shu, HY; Wu, J; Yu, YL, 2021)
"Cumulative recurrence rates at six months did not statistically differ among the three different groups (27% in H pylori negative, 46% in H pylori positive, and 31% in those where H pylori was eradicated during the healing phase), although a numerical trend in favour of a higher recurrence rate in infected patients was evident."2.68Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy. ( Bianchi Porro, G; Caruso, I; Imbesi, V; Montrone, F; Parente, F, 1996)
"Treatment with omeprazole once daily has been shown to be superior to that with ranitidine and misoprostol in this respect."1.30Quality of life in arthritis patients using nonsteroidal anti-inflammatory drugs. ( Wiklund, I, 1999)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (20.00)18.2507
2000's9 (60.00)29.6817
2010's2 (13.33)24.3611
2020's1 (6.67)2.80

Authors

AuthorsStudies
Chen, LZ1
Shu, HY1
Wu, J1
Yu, YL1
Ma, D1
Huang, X1
Liu, MM1
Liu, XH1
Shi, JB1
Blackler, R1
Syer, S1
Bolla, M1
Ongini, E1
Wallace, JL1
Kellner, HL1
Li, C1
Essex, MN1
Chan, FK4
Hung, LC2
Suen, BY2
Wu, JC3
Lee, KC1
Leung, VK1
Hui, AJ2
To, KF3
Leung, WK3
Wong, VW2
Chung, SC2
Sung, JJ3
Graham, DY1
Maev, IV1
V'iuchnova, ES1
Staseva, IV1
Curran, MP1
Wellington, K1
Lee, YT1
Cryer, B1
Spiegel, BM1
Chiou, CF1
Ofman, JJ1
Peura, D1
Wilcox, CM1
Niculescu, L1
Berger, M1
Beutler, M1
Hartmann, K1
Kuhn, M1
Gartmann, J1
Bianchi Porro, G1
Parente, F1
Imbesi, V1
Montrone, F1
Caruso, I1
Wiklund, I1
Yung, MY1
Kwok, T1
Hui, Y1
Chan, HL1
Chan, CS1
Hui, E1
Woo, J1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain[NCT00365976]Phase 458 participants (Actual)Interventional2006-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Hamilton Depression Rating Scale (HAM-D-24)

The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe. (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4

,
Interventionunits on a scale (Mean)
prenaprosyn Baselinepostnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone6.456.384.544.142.62
Placebo7.106.575.535.076.21

Insomnia Severity Index (ISI)

The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia). (NCT00365976)
Timeframe: Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionunits on a scale (Mean)
Prenaprosyn BaselinePostnaprosyn baselineWeek 1Week 2Week 4
Eszopiclone18.8518.0011.2810.618.38
Placebo20.2616.7812.8512.7413.75

Mean Sleep Onset Latency (SOL)

(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionminutes (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone38.2822.3617.5015.28
Placebo34.1127.0023.1019.91

Mean Subjective Sleep Diary Derived Total Sleep Time (TST)

Nightly total sleep time was averaged from diary entries. (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, week 2, week 4

,
InterventionMinutes (Mean)
postnaprosyn baselineweek 1week 2Week 4
Eszopiclone316.96403.47421.97411.97
Placebo380.45375.56382.11388.96

Number of Awakenings

(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionawakenings (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone2.291.311.351.33
Placebo2.081.982.132.34

Patient Global Impression of Pain Ratings

Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain) (NCT00365976)
Timeframe: postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionunits on a scale (Mean)
postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone4.023.543.303.08
Placebo3.903.824.013.80

Roland Morris Low Back Pain Inventory (RMLBPI)

"The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 yes-no items assessing potential disabilities.~Scores range from 0 (no disability) to 24 (severe disability)." (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4

,
Interventionunits on a scale (Mean)
prenaprosyn Baselinepostnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone12.279.979.107.636.59
Placebo11.3310.309.059.327.94

Sleep Quality Ratings

Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep (NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionunits on a scale (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone4.525.996.186.38
Placebo4.444.905.335.29

Visual Analog Scale Pain Ratings (VAS)

Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, Week 2, Week 4

,
Interventionunits on a scale (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone48.5140.7234.7031.69
Placebo53.7951.9951.2551.60

Wake Time After Sleep Onset

(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionminutes (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone91.5149.3437.0736.74
Placebo81.4376.7181.3276.18

Reviews

2 reviews available for omeprazole and Polyarthritis

ArticleYear
Delayed-release lansoprazole plus naproxen.
    Drugs, 2004, Volume: 64, Issue:17

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents;

2004
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
    Arthritis and rheumatism, 2005, Apr-15, Volume: 53, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin

2005

Trials

6 trials available for omeprazole and Polyarthritis

ArticleYear
Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.
    Current medical research and opinion, 2012, Volume: 28, Issue:9

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Di

2012
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
    The New England journal of medicine, 2002, Dec-26, Volume: 347, Issue:26

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2;

2002
[Comparative efficacy of different therapeutic schemes in gastropathies induced by nonsteroid anti-inflammatory drugs].
    Terapevticheskii arkhiv, 2004, Volume: 76, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Drug Administration Schedule;

2004
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
    Gastroenterology, 2004, Volume: 127, Issue:4

    Topics: Adult; Aged; Arthritis; Celecoxib; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dyspe

2004
Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.
    Gut, 1996, Volume: 39, Issue:1

    Topics: Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Drug Therapy, Co

1996
Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.
    Lancet (London, England), 2002, Jan-05, Volume: 359, Issue:9300

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Delayed-Action Preparations;

2002

Other Studies

7 other studies available for omeprazole and Polyarthritis

ArticleYear
Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis.
    European journal of medicinal chemistry, 2021, Mar-05, Volume: 213

    Topics: Administration, Oral; Animals; Arthritis; Cells, Cultured; Dimerization; Disease Models, Animal; Dos

2021
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combi

2012
NSAIDs, Helicobacter pylori, and Pandora's Box.
    The New England journal of medicine, 2002, Dec-26, Volume: 347, Issue:26

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2;

2002
COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
    Gastroenterology, 2004, Volume: 127, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxyge

2004
Response to Ray and colleagues: the called-for large clinical trial is already ongoing.
    Gastroenterology, 2008, Volume: 134, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Diclofenac; Humans

2008
Arthralgias and omeprazole.
    BMJ (Clinical research ed.), 1994, Dec-17, Volume: 309, Issue:6969

    Topics: Adult; Aged; Arthralgia; Arthritis; Erythema Nodosum; Female; Humans; Male; Middle Aged; Omeprazole

1994
Quality of life in arthritis patients using nonsteroidal anti-inflammatory drugs.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 1999, Volume: 13, Issue:2

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Female; Humans; Male; M

1999